A wave of pharmaceutical litigation is building in 2026 around a drug most Americans have never heard of. Tavneos (avacopan), approved in October 2021 to treat a rare autoimmune condition called ANCA-associated vasculitis, is now at the center of federal regulatory action and an emerging Tavneos liver injury lawsuit investigation. Following a March 2026 FDA safety communication identifying 76 drug-induced liver injury (DILI) cases — including fatal outcomes — and a proposed withdrawal of the drug’s approval in April 2026, the plaintiff bar is moving quickly. If you or a loved one took Tavneos and suffered liver damage, bile duct destruction, or liver failure, here is what you need to know right now.
What Is Tavneos and Why Did the FDA Take Action in 2026?
Tavneos (avacopan) is a complement inhibitor manufactured by Amgen, approved by the U.S. Food and Drug Administration in October 2021 for the treatment of ANCA-associated vasculitis — a serious condition causing inflammation of blood vessel walls. The drug was marketed as a steroid-sparing alternative, offering patients a way to manage their disease without the long-term side effects of corticosteroids. For a small but vulnerable patient population, it represented real hope.
That hope has been severely complicated by what regulators found in postmarket surveillance. On March 31, 2026, the FDA issued a formal safety communication identifying 76 confirmed cases of drug-induced liver injury linked to Tavneos, including cases resulting in death. This was not a minor label update — it was a significant public health warning flagging a pattern the agency had been tracking since the drug entered the market. Then, on April 27, 2026, the FDA escalated further by proposing withdrawal of Tavneos’ approval, citing both effectiveness concerns and material misstatements in the drug’s labeling. Amgen, notably, had reportedly refused an earlier FDA request to voluntarily withdraw the drug — a posture that legal analysts say will become a central issue in any Tavneos liver injury lawsuit that moves forward.
The Medical Reality: Vanishing Bile Duct Syndrome and Liver Failure
Understanding why plaintiffs’ attorneys are paying close attention to Tavneos requires understanding the specific type of liver injury at issue. Among the most serious conditions linked to the drug is vanishing bile duct syndrome (VBDS) — a progressive and often irreversible condition in which the small bile ducts inside the liver are gradually destroyed. Unlike typical drug-induced hepatitis, which may resolve after discontinuation, VBDS causes permanent structural damage to the liver. Once bile ducts are destroyed, the liver loses its ability to drain bile properly, leading to toxic bile acid accumulation, cirrhosis, and in severe cases, complete liver failure requiring transplantation.
According to information compiled by the National Institute of Diabetes and Digestive and Kidney Diseases, drug-induced liver injury is one of the leading causes of acute liver failure in the United States, and vanishing bile duct syndrome represents one of its most devastating subtypes. For Tavneos patients who developed VBDS, early symptoms — fatigue, jaundice, itching, abdominal discomfort — may have been dismissed or attributed to their underlying vasculitis. The delay between drug exposure and recognized liver injury is precisely the kind of gap that plaintiffs allege Amgen should have warned physicians about far sooner than it did.
Key FDA Actions and Case Data: 2026 Timeline
| Date | Event | Key Detail |
|---|---|---|
| October 2021 | FDA approves Tavneos (avacopan) | Approved for ANCA-associated vasculitis treatment |
| March 31, 2026 | FDA issues DILI safety communication | 76 confirmed liver injury cases, including fatal outcomes |
| April 27, 2026 | FDA proposes withdrawal of Tavneos approval | Cites effectiveness concerns and material label misstatements |
| April 2026 | Amgen declines voluntary withdrawal | Company contests FDA’s proposed action |
| Ongoing 2026 | Plaintiff bar opens Tavneos investigation | Failure-to-warn claims being evaluated nationally |
This timeline matters enormously for potential claimants. The FDA’s actions in 2026 create documented, official evidence that a known risk existed and that the drug’s labeling — as it stood for years after approval — failed to adequately communicate that risk to prescribing physicians and their patients.
The Legal Theory: Failure to Warn and Inadequate Labeling
The core legal theory driving the emerging Tavneos liver injury lawsuit landscape is failure to warn — one of the most well-established product liability claims in pharmaceutical litigation. Under U.S. law, drug manufacturers have a continuous, ongoing duty to update their product labeling as postmarket safety signals emerge. This duty does not end at FDA approval; it extends throughout the life of the product on the market.
Plaintiffs allege that as postmarket reports of liver injury, VBDS, and liver failure accumulated following Tavneos’ October 2021 approval, Amgen had both the legal obligation and the practical ability to issue updated warnings — including Dear Doctor letters, label revisions, and direct healthcare provider communications — and failed to do so in a timely manner. Under the learned intermediary doctrine, pharmaceutical companies must ensure that prescribing physicians have complete, accurate, and current information about a drug’s risks so they can counsel patients appropriately. When that chain breaks — when a company sits on safety signals instead of escalating them — patients are left making treatment decisions without the information they need. You can review the foundational framework for pharmaceutical product liability at Cornell Law School’s Legal Information Institute.
The fact that Amgen reportedly refused the FDA’s voluntary withdrawal request adds another dimension to potential litigation. In pharmaceutical liability cases, a manufacturer’s response to regulatory pressure — including whether they cooperated or resisted safety-driven requests — is frequently introduced as evidence of corporate conduct relevant to punitive damages.
Who May Be Eligible to File a Tavneos Liver Injury Lawsuit?
Attorneys investigating potential Tavneos liver injury lawsuit claims are focusing on individuals who meet several key criteria. While every case is fact-specific and requires individual legal evaluation, the general profile of a potential claimant includes:
- Patients who were prescribed and took Tavneos (avacopan) after its October 2021 approval
- Individuals diagnosed with drug-induced liver injury (DILI), vanishing bile duct syndrome (VBDS), liver failure, or other serious hepatic conditions
- Family members of patients who died from liver failure potentially linked to Tavneos use
- Patients whose liver injury resulted in hospitalization, transplant evaluation, or permanent organ damage
- Individuals who were not adequately warned about the risks of liver damage prior to starting the medication
Because ANCA-associated vasculitis is a rare condition, the overall Tavneos patient population is smaller than typical mass tort drugs. However, the severity of injuries — particularly VBDS and fatal liver failure — means individual case values may be substantial. Legal analysts tracking pharmaceutical litigation in 2026 have noted that early-stage serious injury cases in emerging drug litigation frameworks have historically projected into the $100,000 to $500,000 range for severe individual injuries, mirroring settlement frameworks seen in GLP-1 receptor agonist litigation. If you want a preliminary sense of potential case value, you can explore a personal injury settlement calculator as a starting point — though only an attorney can evaluate your specific claim.
For families who lost a loved one to Tavneos-related liver failure, wrongful death claims may also be available. These cases involve a distinct set of damages — including loss of companionship, financial support, and funeral expenses — and a wrongful death calculator can help families begin to understand the scope of recoverable losses before consulting with an attorney.
How This Litigation Compares to Other 2026 Pharmaceutical Cases
The Tavneos liver injury lawsuit investigation shares structural similarities with some of the most significant pharmaceutical liability waves of recent years, but it occupies a unique and urgent position: it is at the beginning of the litigation cycle, not the end. Unlike talc, proton pump inhibitor (PPI), or GLP-1 litigation — all of which have progressed to settlements, verdicts, or multidistrict litigation consolidation — Tavneos claims are still in the investigation and early filing phase as of 2026. This is significant for two reasons.
First, early-stage claimants in pharmaceutical mass torts historically have more leverage in settlement negotiations than those who join after a global resolution framework is already in place. Second, statutes of limitations — which vary by state and typically begin running from the date of injury discovery or the date a plaintiff reasonably should have known about the drug connection — are actively ticking. The FDA’s March and April 2026 communications may constitute the legal “trigger” for discovery in many states, meaning the window to act without limitation concerns may be narrower than many potential claimants realize. State-specific limitation periods can be reviewed through resources like Justia’s statute of limitations overview.
Frequently Asked Questions About Tavneos Liver Injury Lawsuits
What is a Tavneos liver injury lawsuit and who can file one?
A Tavneos liver injury lawsuit is a personal injury or wrongful death claim filed against Amgen, the manufacturer of Tavneos (avacopan), alleging that the company failed to adequately warn patients and physicians about the risk of serious liver injuries — including drug-induced liver injury (DILI), vanishing bile duct syndrome (VBDS), and liver failure. Individuals who took Tavneos after its October 2021 approval and subsequently developed serious liver conditions may have standing to file a claim. Family members of patients who died from Tavneos-related liver failure may also pursue wrongful death actions. Eligibility is case-specific and should be evaluated by a licensed attorney.
What injuries are linked to Tavneos (avacopan) in 2026?
The FDA’s March 2026 safety communication identified 76 cases of drug-induced liver injury associated with Tavneos, including cases with fatal outcomes. Among the most serious conditions identified is vanishing bile duct syndrome (VBDS), a progressive condition in which bile ducts inside the liver are permanently destroyed, potentially leading to cirrhosis, liver failure, and the need for transplantation. These injuries are considered severe because VBDS is often irreversible — unlike some forms of drug-induced hepatitis, liver damage from bile duct destruction does not fully heal after the drug is stopped.
Why is Amgen being sued if Tavneos was FDA-approved?
FDA approval does not shield drug manufacturers from civil liability. Under U.S. pharmaceutical product liability law, companies have a continuing duty to update warnings as new safety signals emerge from postmarket surveillance. Plaintiffs allege that Amgen was aware of — or should have been aware of — liver injury signals after Tavneos entered the market in 2021 and failed to update the drug’s labeling, issue Dear Doctor letters, or otherwise alert prescribing physicians in a timely manner. The FDA’s April 2026 proposed withdrawal, which cited material misstatements in Tavneos labeling, and Amgen’s reported refusal to voluntarily pull the drug, are expected to play central roles in litigation.
How much could a Tavneos liver injury lawsuit be worth?
Individual case values in emerging pharmaceutical litigation depend on the severity of injury, degree of permanent harm, medical expenses, lost wages, and other damages. Legal analysts tracking 2026 pharmaceutical liability trends have noted that serious injury cases in newly emerging drug tort frameworks — particularly those involving permanent organ damage or death — have historically been projected in the range of $100,000 to $500,000 or more for severe individual injuries, based on frameworks seen in comparable litigation. Because Tavneos litigation has not yet reached a global settlement stage, early filers may have greater negotiating leverage. A personal injury attorney can evaluate the specific facts of your case to provide a realistic assessment.
Is there a deadline to file a Tavneos liver injury lawsuit?
Yes. Statutes of limitations — the legal deadlines for filing personal injury and wrongful death claims — vary by state, typically ranging from one to three years. In pharmaceutical cases, the clock often begins running from the date a plaintiff knew or reasonably should have known that their injury was connected to the drug in question. The FDA’s March 31 and April 27, 2026 safety communications and proposed withdrawal may constitute the legal “discovery trigger” for many potential claimants, meaning time is actively running. Waiting too long can permanently bar you from recovering compensation. Contacting a personal injury attorney as soon as possible is strongly advised.
This article is provided for informational and educational purposes only and does not constitute legal advice; readers should consult a licensed personal injury attorney in their jurisdiction for guidance specific to their individual circumstances.
Related reading: $45 Million Verdict: How Wrongful Death Damages Are Calculated When A Baby Powder Maker Hides An Asbestos Risk For Decades
Thomas B. Harrison is a personal injury legal consultant with extensive experience connecting injury victims with qualified attorneys across the United States. He specializes in helping people understand when they need legal representation and how to find the right personal injury attorney for their specific situation. Thomas is not an attorney and the information he provides is for educational purposes only.